LINC02994: A Potential Drug Target and Biomarker (G101928978)

Target Name: LINC02994

NCBI ID: G101928978

LINC02994

Other Name(s): Uncharacterized LOC101928978, transcript variant X2 | Long intergenic non-protein coding RNA 2994 | long intergenic non-protein coding RNA 2994 | LOC101928978 variant X2

LINC02994: A Potential Drug Target and Biomarker

LINC02994 is a long non-coding RNA (lncRNA) that has been identified using RNA-seq technology as expressed in various tissues and cell types, including brain, heart, and muscle. The RNA-seq data has revealed that LINC02994 is highly expressed in the brain and has been implicated in the development and progression of various neurological diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

One of the key features of LINC02994 is its highly conserved gene structure, with a typical exon-intron structure and a single exon at its 5' end. This gene has four known splice variants, designated as LINC02994-1, LINC02994-2, LINC02994-3, and LINC02994-4, each of which has a unique 3' UTR region.

The 3' UTR region plays a crucial role in regulating gene expression and has been implicated in various functions, including splicing, translation, and RNA stability. Therefore, analyzing the 3' UTR regions of LINC02994 can provide insights into its functional organization and potential drug targets.

Several studies have identified potential LINC02994-3 and LINC02994-4 binding sites in the 3' UTR region that are conserved across the different splice variants. These binding sites are located in the region between exon 2 and exon 3 and are characterized by a higher-than-average interaction with the protein encoded by the LINC02994 gene.

The conservation of the LINC02994-3 and LINC02994-4 binding sites in the 3' UTR region suggests that they may be important for the regulation of LINC02994 gene expression. Moreover, these binding sites may be potential drug targets that can be targeted by small molecules or other therapeutic agents.

In addition to its potential drug targets, LINC02994 has also been implicated in the development and progression of various neurological diseases. The RNA-seq data has shown that LINC02994 is highly expressed in the brain and has been associated with the pathophysiology of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The expression of LINC02994 has also been correlated with the expression of other genes that are known to be involved in the development and progression of these disorders. For example, LINC02994 has been shown to be highly expressed in the brains of individuals with Alzheimer's disease and has been associated with the expression of genes that are involved in the development of neurodegeneration in this disease.

In conclusion, LINC02994 is a promising candidate for drug targeting and biomarker development in the context of neurological diseases. The conservation of its binding sites in the 3' UTR region and its association with the development and progression of these disorders make it an attractive target for small molecules and other therapeutic agents. Further studies are needed to determine the functional implications of LINC02994 and to develop strategies for its characterization as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2994

The "LINC02994 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02994 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets